4CPS-142 Analysis of prescribing and clinical outcomes of vedolizumab treatment in a university care hospital

BACKGROUND: Vedolizumab became available in mid-2014 for the treatment of moderate to severe Crohn’s disease (CD) and ulcerative colitis (UC). The Spanish Drug Agency provided a Therapeutic Positioning Report about the clinical recommendation in the use of vedolizumab and its public funds. PURPOSE:...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Sanchez, E, Yañez, D, Carrion, IM, Montero, O, Martin, CB
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 4: Clinical pharmacy services
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535458/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.233
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky